Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
|Videos|October 23, 2017
Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma
Author(s)Celeste Lebbe, MD, PhD
Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.
Advertisement
Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.
In a phase II study of avelumab, chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma, first-line treatment resulted in early responses and a high overall response rate (ORR) in this difficult-to-treat population.
The ORR was 62%, which occurred quite rapidly, says Lebbe. The median duration of response is not yet reached, though.
Advertisement
Related to this article
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
5